Functional genomics approaches for the identification and validation of antifungal drug targets

American Journal of PharmacoGenomics

Volumn 2, Issue 2, 2002, Pages 113-127

  De Backer, M D ^a,b   Van Dijck, P ^c   Luyten, W H M L ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BUTENAFINE; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; GLYMINOX; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; RNA; TERBINAFINE; TRIAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

CLINICAL TRIAL; DNA MICROARRAY; DRUG TARGETING; FLUORESCENCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INACTIVATION; GENETIC SCREENING; GENOMICS; HUMAN; MUTAGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; TRANSPOSON; VALIDATION PROCESS; ANIMAL; DRUG DELIVERY SYSTEM; METHODOLOGY; PHARMACEUTICS; VALIDATION STUDY;

FUNGI; TRANSPOSONS;

ANIMALS; ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036326464     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200202020-00004     Document Type: Review

References (130)

1. Pathogenic fungi in the 21 st century
2. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
3. Fungal infection rates are increasing
4. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century
5. Emerging disease issues and fungal pathogens associated with HIV infection
6. Opportunistic candidiasis: An epidemic of the 1980s
7. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
8. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
9. Estimating the cost of nosocomial candidemia in the United States
10. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
11. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center
12. Crisis in infectious diseases: Time for a new paradigm?
13. The search for new antifungal drugs and strategies continues
14. Target-based drug discovery for the development of novel anti-infectives
15. Harnessing the power of the genome in the search for new antibiotics
16. The sequence of the human genome
17. Whole genomes: The foundation of new biology and medicine
18. Genomics and antimicrobial drug discovery
19. Mining bacterial genomes for antimicrobial targets
20. Bacterial targets and antibiotics: Genome-based drug discovery
21. Impact of genomics on drug discovery and clinical medicine
22. Gene expression-based responses to drug treatment
23. Expression monitoring by hybridization to high-density oligonucleotide arrays
24. Exploring the new world of the genome with DNA microarrays
25. Expression profiling using cDNA microarrays
26. Powerful tools for genetic analysis come of age
27. The application of DNA microarrays in gene expression analysis
28. Cluster analysis and display of genomewide expression patterns
29. The transcriptional program of sporulation in budding yeast
30. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray
31. Analysis of drug pharmacology towards predicting drug behaviour by expression profiling using high-density oligonucleotide arrays
32. Widespread aneuploidy revealed by DNA microarray expression profiling
33. Drug target validation and identification of secondary drug target effects using DNA microarrays
34. A reporter gene assay for fungal sterol biosynthesis inhibitors
35. TOR controls translation initiation and early G1 progression in yeast
36. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins
37. Exploring the metabolic and genetic control of gene expression on a genomic scale
38. Genomewide studies of histone deacetylase function in yeast
39. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p
40. The histone deacetylase genes HDA1 and RPD3 play distinct roles in regulation of high-frequency phenotypic switching in Candida albicans
41. PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1
42. PDR3, a new regulatory gene, is homologous to PDRI and controls the multidrug resistance phenomenon
43. Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants
44. Global response of Saccharomyces cerevisiae to an alkylating agent
45. Cytochromes P450 in fungi
46. Anti-Candida drugs: The biochemical basis for their activity
47. Hypothesis on the molecular basis of the antifungal activation of N-substituted imidazoles and triazoles
48. Genome-wide expression patterns in Saccharomyces cerevisiae: Comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol
49. Laser capture microdissection
50. The glyoxylate cycle is required for fungal virulence
51. Thermotolerance in Saccharomyces cerevisiae. The Yin and Yang of trehalose
52. Intracellular trehalose improves survival of cryopreserved mammalian cells
53. Trehalose expression confers desiccation tolerance on human cells
54. Disruption of the Candida albicans TPS1 gene encoding trehalose-6-phosphate synthase impairs formation of hyphae and decreases infectivity
55. Trehalose hydrolysis is not required for human serum-induced dimorphic transition in Candida albicans: Evidence from a tps1/tps1 mutant deficient in trehalose synthesis
56. Disruption of the Candida albicans TPS2 gene encoding trehalose-6-phosphate phosphatase decreases infectivity without affecting hyphae formation
57. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
58. Identification of yeast meiosis-specific genes by differential display
59. Identification of genes with nutrient-controlled expresion by PCR-mapping in the yeast Saccharomyces cerevisiae
60. Application of mRNA differential display to investigate gene expression in thermotolerant cells of Saccharomyces cerevisiae
61. Three genes whose expression is induced by stress in Saccharomyces cerevisiae
62. Screening of genes involved in isooctane tolerance in Saccharomyces cerevisiae by using mRNA differential display
63. Up-regulation of two Candida albicans genes in the rat model of oral candidiasis detected by differential display
64. Host response and Histoplasma capsulatum/macrophage molecular interactions
65. Molecular cloning of a gene encoding translation initiation factor (TIF) from Candida albicans
66. Changes in Aspergillus nidulans gene expression induced by bafilomycin, a Streptomyces-produced antibiotic
67. Applications of differential -display reverse transcription-PCR to molecular pathogenesis and medical mycology
68. Serial analysis of gene expression
69. High-throughput gene expression analysis using SAGE
70. In vitro cloning of complex mixtures of DNA on microbeads: Physical separation of differentially expressed cDNAs
71. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays
72. Antisense: A key tool for cell and developmental studies in Dictyostelium
73. Gene regulation by antisense RNA in the fission yeast Schizosaccharomyces pombe
74. The ade6 gene of the fission yeast as a target for antisense and ribozyme RNA-mediated suppression
75. The influence of antisense gene location on target gene suppression in the fission yeast Schizosaccharomyces pombe
76. Artificial ribozyme and antisense gene expression in S. cerevisiae
77. Antisense gene expression in yeast
78. YBR1012, an essential gene from S. cerevisiae: Construction of an RNA-antisense conditional allele and isolation of a multicopy suppressor
79. Artificial antisense regulation of YBR1012 an essential gene from S. cerevisiae which is important for progression through G1/S
80. Inhibition of Neurospora crassa growth by a glucan synthase-1 antisense construct
81. Antisense silencing of the creA gene in Aspergillus nidulans
82. Sequence analysis, overexpression, and antisense inhibition of a B-xylosidase gene, xylA, from Aspergillus oryzae KBN616
83. Construction of a low-serine-type carboxypeptidase producing mutant of Aspergillus oryzae by the expression of antisense RNA and its use as a host for heterologous protein secretion
84. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans
85. Recent developments in molecular genetics of Candida albicans
86. Induction of mating in Candida albicans by construction of MTLa and MTLalpha strains
87. Evidence for mating of the 'asexual' yeast Candida albicans in a mammalian host
88. Genomic evidence for a complete sexual cycle in Candida albicans
89. Isolation of an aminoglycoside hypersensitive mutant and its application in screening
90. A screening method for cell-wall inhibitors using a D-cycloserine hypersensitive mutant
91. Development of cell-based assays and screens in Saccharomyces through the combination of molecular and classical genetics
92. Protein synthesis in yeast. Structural and functional analysis of the gene encoding elongation factor 3
93. Lanomycin and glucolanomycin, antifungal agents produced by Pycnidiophora dispersa
94. Construction and growth properties of a yeast strain defective in sterol 14-alpha-reductase
95. Genomic profiling of drug sensitivities via induced haploinsufficiency
96. Redundancy reveals drugs in action
97. Integrating genetic approaches into the discovery of anticancer drugs
98. Stable transformation and regulated expression of an inducible reporter construct in Candida albicans using restriction enzyme-mediated integration
99. Insertional mutagenesis of Aspergillus fumigatus
100. Promoter-tagged REMI mutagenesis in Aspergillus niger
101. Tagging of genes involved in multidrug resistance in Aspergillus nidulans
102. Emerging technologies in yeast genomics
103. Multipurpose transposon system for analyzing protein production, localization, and function in Saccharomyces cerevisiae
104. Genetic footprinting: A genomic strategy for determining a gene's function given its sequence
105. Multicellular ascomycetous fungal genomes contain more than 8000 genes
106. Gene discovery and gene function assignment in filamentous fungi
107. Simultaneous identification of bacterial virulence genes by negative selection
108. An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells
109. Signature-tagged and directed mutagenesis identify PABA synthetase as essential for Aspergillus fumigatus pathogenicity
110. Identification of virulence mutants of the fungal pathogen Cryptococcus neoformans using signature-tagged mutagenesis
111. Insertional mutagenesis of pathogenic fungi
112. Host-induced, stage-specific virulence gene activation in Candida albicans during infection
113. Applying in vivo expression technology (IVET) to the fungal pathogen Histoplasma capsulatum
114. Drug-induced phenotypes provide a tool for the functional analysis of yeast genes
115. Bacterial genetics by flow cytometry: Rapid isolation of Salmonella typhimurium acid-inducible promoters by differential fluorescence induction
116. Fluorescence-based isolation of bacterial genes expressed within host cells
117. Regulation of both gene expression and protein stability provides genetically assisted target evaluation (GATE) for microbial target validation
118. RNA interference: Genetic wand and genetic watchdog
119. Post-transcriptional gene silencing by double-stranded RNA
120. RNA-mediated interference as a tool for identifying drug targets
121. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nt intervals
122. Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy
123. An active retrotransposon in Candida albicans